Addition Therapeutics
South San Francisco, US · 7 known investors
Addition Therapeutics develops genetic medicines using its all-RNA, non-viral, LNP-based PRINT platform, which combines the profile of RNA therapeutics with the durability of gene therapies. The company is advancing a pipeline of one-time therapies for chronic and rare severe diseases, including obesity, Fabry, HIV, and ocular disease.
BiotechHealthtech
Investors · 7
SR One Capital ManagementRedwood City
AbingworthreportedLondon · $15M – $30M
Osage University PartnersreportedBala Cynwyd
Pivotal Life SciencesreportedSan Francisco
Also in the syndicate · 3
BEVCGates FoundationSR One
Funding
SEC filings, press & company announcements$100M disclosed across 1 round · 2025
- $100MraisedDec 2025 · 5 sources
Abingworth, BEVC, Gates Foundation, Osage University Partners, Pivotal Life Sciences, SR One
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Addition Therapeutics do?
- Addition Therapeutics develops genetic medicines using its all-RNA, non-viral, LNP-based PRINT platform, which combines the profile of RNA therapeutics with the durability of gene therapies. The company is advancing a pipeline of one-time therapies for chronic and rare severe diseases, including obesity, Fabry, HIV, and ocular disease.
- Who are Addition Therapeutics's investors?
- Addition Therapeutics's investors include SR One Capital Management, Abingworth, Osage University Partners, Pivotal Life Sciences.
- How much funding has Addition Therapeutics raised?
- Addition Therapeutics has disclosed $100M raised across 1 round.
- Where is Addition Therapeutics headquartered?
- Addition Therapeutics is headquartered in South San Francisco, US.